A white paper released by Project PAUSE on November 19, 2025, assesses the impact of the Nursing Home Care Compare long-stay antipsychotics quality measure on access to appropriate treatment for nursing home residents experiencing neuropsychiatric symptoms related to Alzheimer’s and related conditions.

Developed by Manatt Health with support from the Alliance for Aging Research, the report asserts several unintended consequences of the measure, including a failure to distinguish between appropriate and inappropriate antipsychotic usage and a failure to reflect current clinical practice guidelines.

Recommendations to the Centers for Medicare and Medicaid Services (CMS) for addressing these issues include revision or removal of the quality measure.

Project PAUSE is a multi-stakeholder coalition, of which LeadingAge is a member, collectively advocates on regulatory issues related to the diagnosis and management of neuropsychiatric symptoms in dementia in long-term care. Learn more about Project PAUSE here.